Janux Therapeutics EBITDA Margin Growth & History (JANX)

Janux Therapeutics's ebitda margin was −1,556.38% for fiscal 2025.

View full Janux Therapeutics company overview

Janux Therapeutics annual ebitda margin history

Janux Therapeutics annual ebitda margin

Fiscal yearPeriod endedEBITDA marginChange (percentage points)
20252025-12-31−1,556.38%−642.26 pp
20242024-12-31−914.12%−35.44 pp
20232023-12-31−878.68%−109.41 pp
20222022-12-31−769.28%+133.01 pp
20212021-12-31−902.28%

Janux Therapeutics ebitda margin trends

Between the periods ended 2021-12-31 and 2025-12-31, Janux Therapeutics's ebitda margin decreased from −902.28% to −1,556.38%, a change of −654.10 percentage points. The latest reported quarter, Q2 2026, shows −304.15%.

About the metric

What EBITDA margin means

EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.

Calculation and source

How EBITDA margin is calculated

TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Janux Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about JANX yet. Start the conversation.

Write the first post